Business Context and Reporting Period
This Form 8-K is filed by Hancock Jaffe Laboratories, Inc. (not Envveno Medical Corp as indicated in metadata) on October 14, 2019. The report addresses a regulatory notice regarding the company's continued listing status on The NASDAQ Stock Market.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance triggering the regulatory notice:
- Stock Price: The closing bid price fell below $1.00 per share for 30 consecutive business days.
Material Changes
The material change reported is the receipt of a notice from Nasdaq indicating non-compliance with the minimum bid price requirement (Rule 5550(a)(2)) for continued listing on the Nasdaq Capital Market.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has an initial 180-day compliance period ending April 13, 2020, to regain compliance.
- Remediation Requirement: To remain listed, the closing bid price must meet or exceed $1.00 per share for 10 consecutive business days prior to the April 13, 2020 deadline.
- Management Intent: Management intends to resolve the situation to allow for continued listing.
- Delisting Risk: If compliance is not met by the deadline, the company may be eligible for an additional grace period if it meets other listing standards (e.g., market value of publicly held shares). Failure to cure the deficiency or qualify for an extension could result in delisting.
- Appeal Rights: The company retains the right to appeal a delisting determination, during which the stock would remain listed.
Investor Verification Checklist
- Verify the current trading price of HJLI to assess the likelihood of meeting the $1.00 threshold within the 180-day window.
- Monitor subsequent filings for any reverse stock split announcements or other capital structure changes intended to raise the share price.
- Check the company's market value of publicly held shares to determine eligibility for a second compliance period if the initial deadline is missed.
- Review the company's cash position and liquidity to ensure it can sustain operations if the stock is delisted to the OTC market.